Family Dollar comments on Icahn letter: 'As previously announced the Company is undertaking an in-depth business review' (FDO)
SunOpta announces Opta Minerals reviewing strategic options (STKL)
AK Steel sees Q2 adjusted loss of ($0.06) to ($0.02) per share vs $0.10 Capital IQ Consensus Estimate (AKS)
SunEdison and BlueWave Capital agree to 50 MW solar asset portfolio acquisition (SUNE)
Chelsea Therapeutics: NORTHERA clinical trial data published in Neurology; Data supported FDA-label for patients with symptomatic neurogenic orthostatic hypotension (CHTP)
Cubist Pharma announces acceptance of Ceftolozane/Tazobactam New Drug Application with priority review (CBST)
Merrimack Pharma to regain worldwide rights to develop and commercialize MM-121; Merrimack to pursue registration path for MM-121 and partnership opportunities (MACK)
Smith & Wesson beats by $0.04, beats on revs; guides Q1, FY15 EPS and rev below consensus (SWHC)
TIBCO Software beats by $0.01, reports revs in-line (TIBX)
Vascular Solutions announces U.S. market launch of its Gel-Bead embolization spheres for the treatment of hypervascular tumors (VASC)
Oracle misses by $0.03, misses on revs (ORCL)
WebMD Health commences litigation against Everyday Health (EVDY) for trademark infringement (WBMD)
Celgene looks like a buy, Barron's says CELG
Raging Capital reports 10.3% passive stake in 1-800-Flowers.com FLWS
Molycorp downgraded to Caa2 from Caa1 by Moody's, outlook stable. MCP
D.E. Shaw reports 5.0% passive stake in Allison Transmission ALSN
Veracyte initiated with an Overweight at Piper Jaffray Target $21. VCYT
SunOpta announces Opta Minerals reviewing strategic options (STKL)
AK Steel sees Q2 adjusted loss of ($0.06) to ($0.02) per share vs $0.10 Capital IQ Consensus Estimate (AKS)
SunEdison and BlueWave Capital agree to 50 MW solar asset portfolio acquisition (SUNE)
Chelsea Therapeutics: NORTHERA clinical trial data published in Neurology; Data supported FDA-label for patients with symptomatic neurogenic orthostatic hypotension (CHTP)
Cubist Pharma announces acceptance of Ceftolozane/Tazobactam New Drug Application with priority review (CBST)
Merrimack Pharma to regain worldwide rights to develop and commercialize MM-121; Merrimack to pursue registration path for MM-121 and partnership opportunities (MACK)
Smith & Wesson beats by $0.04, beats on revs; guides Q1, FY15 EPS and rev below consensus (SWHC)
TIBCO Software beats by $0.01, reports revs in-line (TIBX)
Vascular Solutions announces U.S. market launch of its Gel-Bead embolization spheres for the treatment of hypervascular tumors (VASC)
Oracle misses by $0.03, misses on revs (ORCL)
WebMD Health commences litigation against Everyday Health (EVDY) for trademark infringement (WBMD)
Celgene looks like a buy, Barron's says CELG
Raging Capital reports 10.3% passive stake in 1-800-Flowers.com FLWS
Molycorp downgraded to Caa2 from Caa1 by Moody's, outlook stable. MCP
D.E. Shaw reports 5.0% passive stake in Allison Transmission ALSN
Veracyte initiated with an Overweight at Piper Jaffray Target $21. VCYT
FlashQuotes
Symbol | Last Sale | Change | % Change | Share Volume | Market |
---|---|---|---|---|---|
FDO | ▼ | NYSE | |||
STKL | ▲ | NASDAQ-GS | |||
AKS | ▼ | NYSE | |||
SUNE | ▼ | NYSE | |||
CHTP | ▲ | NASDAQ-CM | |||
CBST | ▲ | NASDAQ-GS | |||
MACK | ▲ | NASDAQ-GM | |||
SWHC | ▲ | NASDAQ-GS | |||
TIBX | ▼ | NASDAQ-GS | |||
VASC | ▲ | NASDAQ-GS | |||
ORCL | ▼ | NYSE | |||
WBMD | ▼ | NASDAQ-GS | |||
CELG | ▲ | NASDAQ-GS | |||
FLWS | ▼ | NASDAQ-GS | |||
MCP | ▲ | NYSE | |||
ALSN | ▲ | NYSE | |||
VCYT | ▲ | NASDAQ-GM |
No comments:
Post a Comment